Results 31 to 40 of about 59,929 (255)
The uPA System Differentially Alters Fibroblast Fate and Profibrotic Ability in Skin Fibrosis
Frontiers in Immunology, 2022 Skin fibrosis is a common pathological feature of various diseases, and few treatment strategies are available because of the molecular pathogenesis is poorly understood.
Ming-Li Zou +15 more
doaj +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Rapid screening of staphylokinase protein variants using an unpurified cell‐free expression system
FEBS Open Bio, EarlyView.An unpurified cell‐free protein synthesis (CFPS) platform enables rapid functional screening of staphylokinase variants. Direct plasminogen‐activation assays performed in microplate format provide real‐time activity readouts, allowing rapid identification and ranking of variants with improved or reduced fibrinolytic activity without protein ...
Maria Tomková +3 more
wiley +1 more source
Microfabricated Anisotropic Myobundles for the Scalable Production of Cardiac Tissue Grafts
Advanced Functional Materials, EarlyView.Controlling the anisotropy of cardiac tissue remains an outstanding challenge in the field of cardiac tissue engineering. Here, we introduce an approach to generate anisotropic cardiac myobundles using cell‐adhesive, synthetic, electrospun fibers and stem cell‐derived cardiac fibroblasts.
Maggie E. Jewett +15 more
wiley +1 more source
Pleiotropic functions of plasminogen activator inhibitor-1 [PDF]
Journal of Thrombosis and Haemostasis, 2005 Plasminogen activator inhibitor-1 (PAI-1), a 45-kDa serine proteinase inhibitor with reactive site peptide bond Arg345-Met346, is the main physiological plasminogen activator inhibitor. It occurs in human plasma at an antigen concentration of about 20 ng mL(-1).
openaire +2 more sources
Cross‐Scale Hierarchical Targeted Delivery System Based on Small‐Scale Magnetic Robots
Advanced Robotics Research, EarlyView.This article reviews a cross‐scale hierarchical targeted delivery system that integrates magnetic continuum robots and magnetic microrobots. By combining rapid long‐range navigation with precise microscale targeting, the system overcomes key limitations of single‐scale approaches.
Junjian Zhou +4 more
wiley +1 more source
Platelets retain high levels of active plasminogen activator inhibitor 1. [PDF]
PLoS ONE, 2011 The vascular fibrinolytic system is crucial for spontaneous lysis of blood clots. Plasminogen activator inhibitor 1 (PAI-1), the principal inhibitor of the key fibrinolytic enzyme tissue-type plasminogen activator (tPA), is present in platelets at high ...
Helén Brogren +4 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor (serpin) superfamily. PAI-1 is the principal inhibitor of the plasminogen activators, tissue plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA)
Gael B. Morrow +3 more
doaj +1 more source
Plasminogen activator inhibitor-1 in cancer research
Biomedicine & Pharmacotherapy, 2018 [Despite as a major inhibitor of urokinase (uPA), paradoxically,] Plasminogen activator inhibitor-1 (PAI-1) has been validated to be highly expressed in various types of tumor biopsy tissues or plasma compared with controls based on huge clinical data bases analysis, more importantly, PAI-1 alone or in conjunction with uPA have been identified as ...
Sijing, Li +5 more
openaire +2 more sources
Advanced Robotics Research, EarlyView.Micro‐ and nanorobots for targeted thrombolysis. This perspective elaborates on the clinical indication of blood clot disorders and current limitations for treatment. As a novel, alternative solution, micro‐ and nanorobots can be used to treat and break down thrombi.
Joshua M. Mesfin +3 more
wiley +1 more source